FUSION IP PLC : Diurnal, raises £335k to complete Chronocort Phase I trial and ... 4-traders Based in Cardiff, Diurnal is developing a novel approach to drug delivery that will help patients suffering from reduced levels of the key hormone cortisol (hydrocortisone). Chronocort® is a modified release therapy that delivers hydrocortisone in a ... |
